Pharmacokinetics of hydromorphone in dogs after intravenous bolus and delivered subcutaneously with the RxActuator Mini-Infuser® infusion pump

2021 ◽  
Vol 48 (6) ◽  
pp. S995-S996
Author(s):  
K. Messenger ◽  
H. Enomoto ◽  
H. Knych ◽  
M. Papich
Keyword(s):  
Infusion Pump ◽  
Intravenous Bolus

scholarly journals OXYTOCIN IV BOLUS VS INFUSION;

2012 ◽  
Vol 19 (03) ◽  
pp. 382-385
Author(s):  
MUHAMMAD ABDULLAH ◽  
RAHEEL - ◽  
TARIQ ABASSI ◽  
Tassaduq Khurshid ◽  
Asim Ghauri
Keyword(s):  
Infusion Pump ◽  
Elective Caesarean Section ◽  
Military Hospital ◽  
Intravenous Bolus ◽  
Hemodynamic Effects ◽  
Haemodynamic Change ◽  
Significant Difference ◽  
Group A ◽  
Group B ◽  
Trial Setting

Introduction: Obstetric texts advocate the use of oxytocin, either intramuscularly or as a dilute infusion, but warn against the useof intravenous bolus oxytocin, fearing significant maternal hemodynamic consequences. Objective: To compare the hemodynamic effects ofoxytocin given intravenous bolus versus infusion form. Study design: Randomized clinical trial. Setting: Study was conducted in mainoperation theatre and OPD of Combined Military Hospital, Rawalpindi. Duration of study: Study was carried out over a period of six monthsfrom 24-03-2009 to 23-09-2009. Subjects and methods: Total 138 patients were included in this study. Patients were divided into two groups(Group-A received oxytocin as bolus of 5 iu given as quickly as possible (approximately over 1 s) and in group-B 5 iu diluted to 20ml normalsaline given over 5 minute using an infusion pump). Each group comprised of 69 patients. Results: Mean age of the patients in group-A was27.3±1.8 and in group-B, 26.9±1.7. Heart rate (beast/min) effect of oxytocin given intravenous bolus vs infusion showed statistically significantdifference from 1 minute to 15 minute (P<0.001). Similarly mean arterial pressure (MAP) rate (beast/min) effect of oxytocin given intravenousbolus vs infusion also showed statistically significant difference from 1 minute to 15 minute (P<0.001). Conclusions: In conclusion, we foundthat at elective Caesarean section, 5 iu of i.v. oxytocin results in less haemodynamic change than 5 iu diluted to 20ml normal saline given over 5min using as an infusion pump.

A Novel Chimaeric Derivative of Saruplase, rscu-PA-40kDA/Hir, Binds to Thrombin and Exerts Thrombus-specific Fibrinolysis in Arterial and Venous Thrombosis in Dogs

1997 ◽  
Vol 77 (03) ◽  
pp. 535-539 ◽  
Author(s):  
J Schneider ◽  
R Hauser ◽  
H-H Hennies ◽  
J Korioth ◽  
G Steffens ◽  
...  
Keyword(s):  
Venous Thrombosis ◽  
Plasma Levels ◽  
Time Course ◽  
Bolus Injection ◽  
Specific Activity ◽  
Intravenous Bolus ◽  
Protease Domain ◽  
Parent Molecule ◽  
Significant Prolongation ◽  
Inhibitory Domain

SummaryThe chimaeric molecule rscu-PA-40kDA/Hir (M23) comprises the kringle and protease domain of saruplase (rscu-PA) and a thrombin inhibitory domain fused to the C-terminus of the protease domain. The 27 amino acid long thrombin inhibitory domain contains a sequence directed to the active site of thrombin and a fragment from the C-terminal region of hirudin. 125I-radiolabelled M23 (0.03 µM) bound to thrombin that was immobilised onto CNBr-activated sepharose beads. Unlabelled M23 (0.01-10 |xM) and hirudin (0.001-10 µµM) concentra-tion-dependently displaced 125I-M23 from its binding to thrombin. Saruplase (up to 10 (iM) did not influence the thrombin binding of M23. The fibrinolytic properties of M23 and saruplase were compared in anaesthetized dogs with femoral artery and saphenous vein thrombosis. Under concomitant heparinization, the intravenous bolus injections of 1 mg/kg M23 or saruplase induced reperfusion of thrombotically occluded femoral arteries in 4 out of 5 treated animals in each case. There was one reocclusion in the M23-treated group. Time to reperfusion (23 ± 4 vs 25 ± 11 min) and maximal height of reperfusion blood flow (98 ± 21 vs 108 ± 15 % of baseline flow) did not differ significantly between the treatment groups. The time course of the lysis of incorporated 125I-fibrin radioactivity in thrombosed saphenous veins was similar after bolus injections of M23 and saruplase. The maximal dissolution of 125I-fibrin in the venous thrombosis model was 91 ± 1 % in M23-and 88 ± 5 % in saruplase-treated animals. Plasma levels of fibrinogen were not influenced and a2-antiplasmin levels were slightly reduced (-27 ± 3 %) after bolus injection of M23. In contrast, bolus injection of saruplase was accompanied by a significant decrease of fibrinogen (-55 ± 19 %) and a2-antiplasmin (-75 ±11%) plasma levels. Template bleeding times virtually did not differ before (2.8 ± 0.3 min) and 60 min after bolus injection of M23 (3.1 ± 0.3 min), whereas treatment with saruplase resulted in a significant prolongation of template bleeding time from 2.6 ± 0.2 min to 28 ± 13 min. It is concluded that the saruplase derivative M23, while inducing equieffective thrombolysis after intravenous bolus injection in dogs, causes much fewer haemostatic side effects than its parent molecule. The high thrombus-specific activity of M23 is tentatively attributed to its affinity to clot-bound thrombin.

High Fibrinopeptide A (FPA) Levels in Acute Non-Lymphocytic Leukemia Are Reduced by Heparin Administration

1984 ◽  
Vol 52 (03) ◽  
pp. 301-304 ◽  
Author(s):  
L Gugliotta ◽  
Silvana Viganò ◽  
A D’Angelo ◽  
Anna Guarini ◽  
S Tura ◽  
...  
Keyword(s):  
Body Temperature ◽  
Blast Cell ◽  
Lymphocytic Leukemia ◽  
Healthy Controls ◽  
Intravenous Bolus ◽  
Fibrinopeptide A ◽  
Cell Counts ◽  
Heparin Administration ◽  
Blast Cells ◽  
Baseline Values

SummaryPlasma levels of fibrinopeptide A (FPA) in 30 untreated patients with acute non-lymphocytic leukemia (ANLL) were significantly higher than in 30 healthy controls (p <0.001). Patients without laboratory signs of disseminated intravascular coagulation (DIC) had levels of FPA higher than controls (p <0.02) but markedly lower than patients with DIC (p <0.001). Five patients with M3 leukemia had a higher mean FPA level (p <0.02) and a lower peripheral blast cell count (p <0.05) than patients with other cytological subtypes of ANLL. When patients with M3 were excluded, a significant correlation was observed between the peripheral blast cell counts and the FPA levels (r = 0.66, p <0.001). FPA levels were similar with body temperature either above or below 38° C. After intravenous bolus of heparin FPA dropped to normal levels in 14 out of 17 patients who had high baseline values. These findings indicate that intravascular thrombin formation, which probably result from the expression of procoagulant activities of blast cells, is the main cause of high FPA in the majority of patients with acute non-lymphocytic leukemia.

The Artificial Pancreas in Cyborg Bodies

2020 ◽  
pp. 412-430
Author(s):  
Anthony Ryan Hatch ◽  
Julia T. Gordon ◽  
Sonya R. Sternlieb
Keyword(s):  
Glucose Sensor ◽  
Social Inequalities ◽  
Infusion Pump ◽  
Artificial Pancreas ◽  
Small Scale ◽  
Glucose Levels ◽  
Loop Design ◽  
Access To Health ◽  
Do It Yourself ◽  
And Control

The new artificial pancreas system includes a body-attached blood glucose sensor that tracks glucose levels, a worn insulin infusion pump that communicates with the sensor, and features new software that integrates the two systems. The artificial pancreas is purportedly revolutionary because of its closed-loop design, which means that the machine can give insulin without direct patient intervention. It can read a blood sugar and administer insulin based on an algorithm. But, the hardware for the corporate artificial pancreas is expensive and its software code is closed-access. Yet, well-educated, tech-savvy diabetics have been fashioning their own fully automated do-it-yourself (DIY) artificial pancreases for years, relying on small-scale manufacturing, open-source software, and inventive repurposing of corporate hardware. In this chapter, we trace the corporate and DIY artificial pancreases as they grapple with issues of design and accessibility in a content where not everyone can become a diabetic cyborg. The corporate artificial pancreas offers the cyborg low levels of agency and no ownership and control over his or her own data; it also requires access to health insurance in order to procure and use the technology. The DIY artificial pancreas offers patients a more robust of agency but also requires high levels of intellectual capital to hack the devices and make the system work safely. We argue that efforts to increase agency, radically democratize biotechnology, and expand information ownership in the DIY movement are characterized by ideologies and social inequalities that also define corporate pathways.

scholarly journals A randomized crossover trial assessing patient preference for two different types of portable infusion-pump devices

1999 ◽  
Vol 10 (6) ◽  
pp. 727-729 ◽  
Author(s):  
D. Zahnd ◽  
S. Aebi ◽  
S. Rusterholz ◽  
M.F. Fey ◽  
M.M. Borner
Keyword(s):  
Patient Preference ◽  
Crossover Trial ◽  
Infusion Pump ◽  
Randomized Crossover Trial ◽  
Different Types

The implantable “Infusaid” infusion pump: The Sydney experience using 5‐fluorouracil

1986 ◽  
Vol 144 (2) ◽  
pp. 74-77 ◽  
Author(s):  
Frederick O. Stephens ◽  
Paul Crea ◽  
Phillip J. Walker
Keyword(s):  
Infusion Pump

Pharmacological properties of YM-254890, a specific Gαq/11 inhibitor, on thrombosis and neointima formation in mice

2005 ◽  
Vol 94 (07) ◽  
pp. 184-192 ◽  
Author(s):  
Masatoshi Taniguchi ◽  
Yumiko Moritani ◽  
Toshio Uemura ◽  
Takeshi Shigenaga ◽  
Hajime Takamatsu ◽  
...  
Keyword(s):  
Oral Administration ◽  
Vascular Injury ◽  
Bolus Injection ◽  
Thrombus Formation ◽  
Therapeutic Window ◽  
Pharmacological Properties ◽  
Neointima Formation ◽  
Intravenous Bolus ◽  
Test Drug ◽  
Intravenous Bolus Injection

SummaryThe pharmacological properties of YM-254890,a specific Gαq/11 inhibitor, on acute thrombosis and chronic neointima formation after vascular injury have been investigated. FeCl3 was used to induce vascular injury in the carotid artery of mice. For the thrombosis studies, the test drug was either intravenously or orally administered before vascular injury. For the neointima studies, the test drug was orally administered 1 h before and twice daily for 1 week after vascular injury. Histological analysis was then performed 3 weeks later. YM-254890 significantly inhibited ex vivo platelet aggregation 5 min after intravenous bolus injection at 0.03 mg/kg or more, and 1 h after oral administration at 1 mg/kg. YM-254890 significantly inhibited thrombus formation after intravenous bolus injection at 0.03 mg/kg as well as after oral administration at 1 mg/kg, but tail transection bleeding time was significantly prolonged at 0.1 mg/kg for intravenous injection and 3 mg/kg for oral administration. Furthermore, oral administration of YM-254890 dose-dependently inhibited neointima formation 3 weeks after vascular injury with significant effects at 1 mg/kg twice daily for 1 week. Clopidogrel also significantly inhibited neointima formation at its antithrombotic dose, but its inhibitory potency was less than that of YM-254890. However, YM-254890 significantly reduced systemic blood pressure at doses 3 times higher than those that produced significant inhibitory effects on thrombosis and neointima formation. Though the systemic use of YM-254890 may be limited, owing to its narrow therapeutic window, this unique compound is a useful research tool for investigating the physiological roles of Gαq/11.

Sign in / Sign up

Export Citation Format

Share Document